M-3251-A-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
Variant has been reported in ClinVar as Likely pathogenic (★★★).
Frequency
Mitomap GenBank:
𝑓 0.0 ( AC: 0 )
Consequence
TRNL1
missense
missense
Scores
Mitotip
Uncertain
Clinical Significance
MM-/-MELAS-with-chorea-ballism
Conservation
PhyloP100: 0.908
Genes affected
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very low frequency in mitomap database: 0.0
PP5
Variant M-3251-A-G is Pathogenic according to our data. Variant chrM-3251-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 9595.Status of the report is reviewed_by_expert_panel, 3 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TRNL1 | unassigned_transcript_4789 use as main transcript | c.22A>G | p.Asn8Asp | missense_variant | 1/1 | |||
RNR2 | unassigned_transcript_4788 use as main transcript | n.*22A>G | downstream_gene_variant | |||||
use as main transcript |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|
Frequencies
GnomAD4 exome Cov.: 0
GnomAD4 exome
Cov.:
0
We have no GnomAD4 genomes data on this position. Probably position not covered by the project.
Mitomap GenBank
AF:
AC:
0
Mitomap
MM-/-MELAS-with-chorea-ballism
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:4
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
MELAS syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Wong Mito Lab, Molecular and Human Genetics, Baylor College of Medicine | Jul 12, 2019 | The NC_012920.1:m.3251A>G variant in MT-TL1 gene is interpreted to be a Pathogenic variant based on the modified ACMG guidelines (unpublished). This variant meets the following evidence codes reported in the guidelines: PS3, PM8, PM9, PP4, PP6 - |
Pathogenic, criteria provided, single submitter | clinical testing | Mendelics | May 04, 2022 | - - |
Mitochondrial disease Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | ClinGen Mitochondrial Disease Nuclear and Mitochondrial Variant Curation Expert Panel, ClinGen | Apr 22, 2024 | The m.3251A>G variant in MT-TL1 has been reported in four unrelated individuals with primary mitochondrial disease to date. Age of onset ranged from the first decade of life to adulthood and clinical features in affected individuals were variably consistent with chronic progressive external ophthalmoplegia (CPEO), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), and early death. Heteroplasmy ranged from 13-95% in affected individuals (PS4_moderate; PMIDs: 8265770, 38465286, 8786060, 30837005). This variant segregated with clinical manifestations in one family with CPEO, progressive muscle weakness, and early death. The variant was present in the proband at 81% in muscle and 13% in blood and was present in maternal cousins at heteroplasmy levels of 25-16% (PP1; PMID: 8265770). There are no reported de novo occurrences of this variant to our knowledge. This variant is absent in the GenBank dataset, Helix dataset, and gnomAD v3.1.2 (PM2_supporting). Computational predictors are conflicting (MitoTIP: 43.5%; HmtVAR: 0.75). Single fiber testing showed higher levels of the variant in COX-negative fibers (61%, range 15-88%) than in COX-positive fibers (28%, range 3%-86%; p<0.001; PS3_supporting, PMID: 8786060). There is additional evidence showing deleterious effects of this variant on the tRNA (PMID: 33380464). In summary, this variant meets criteria to be classified as uncertain significance for primary mitochondrial disease however, after extensive discussion, this Expert Panel elected to modify the classification to likely pathogenic given the compelling functional validation and consistent phenotype observed in reported cases. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on April 22, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PS4_moderate, PP1, PM2_supporting, PS3_supporting. - |
Progressive external ophthalmoplegia, proximal myopathy, and sudden death Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 1996 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Mitotip
Uncertain
Hmtvar
Pathogenic
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at